988O A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma

Autor: Hamid, O., Rydén, V., Mehmi, I., Wang, D., Patel, M., Krause, J., Sandin, L.C., Grauers Wiktorin, H., Lövgren, T., Eriksson, E., Leja Jarblad, J., Loskog, A., Ullenhag, G.J.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S674-S674

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer.

Autor: Ladjevardi CO; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden., Skribek M; Thoracic Oncology Center, Theme Cancer, Karolinska University Hospital, 171 76, Stockholm, Sweden.; Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden., Koliadi A; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden., Rydén V; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden., El-Naggar AI; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Digkas E; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Mälarsjukhuset, 633 49, Eskilstuna, Sweden., Valachis A; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. antonios.valachis@oru.se., Ullenhag GJ; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Nov 07; Vol. 74 (1), pp. 14. Date of Electronic Publication: 2024 Nov 07.